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BRCA1/2-negative, high-risk breast 
cancers (BRCAX) for Asian women: 
genetic susceptibility loci and their 
potential impacts
Joo-Yeon Lee  1, Jisun Kim2, Sung-Won Kim3, Sue K. Park4,5,6, Sei Hyun Ahn2, Min Hyuk Lee7, 
Young Jin Suh8, Dong-Young Noh6,9, Byung Ho Son  2, Young Up Cho10, Sae Byul Lee2, 
Jong Won Lee  2, John L. Hopper1,11 & Joohon Sung1,12,13
“BRCAX” refers breast cancers occurring in women with a family history predictive of being a BRCA1/2 
mutation carrier, but BRCA1/2 genetic screening has failed to find causal mutations. In this study, we 
report the findings of the genetic architecture of BRCAX with novel and redefined candidate loci and their 
potential impacts on preventive strategy. We performed a genome-wide association study involving 
1,469 BRCAX cases from the Korean Hereditary Breast Cancer study, and high-risk breast cancer cases 
(1,482 Asians and 9,902 Europeans) from the Breast Cancer Association Consortium. We also evaluated 
the previously reported susceptibility loci for their roles in the high-risk breast cancers. We have identified 
three novel loci (PDE7B, UBL3, and a new independent marker in CDKN2B-AS1) associated with BRCAX, 
and replicated previously reported SNPs (24 of 92) and moderate/high-penetrance (seven of 23) genes 
for Korean BRCAX. For the novel candidate loci, evidence supported their roles in regulatory function. We 
estimated that the common low-penetrance loci might explain a substantial part of high-risk breast cancer 
(39.4% for Koreans and 24.0% for Europeans). Our study findings suggest that common genetic markers 
with lower penetrance constitute a part of susceptibility to high-risk breast cancers, with potential 
implications for a more comprehensive genetic screening test.
Breast cancer is the most common female cancer worldwide, and its incidence rate is increasing rapidly in Asian 
populations including South Korea1,2. The National Cancer Screening Program in Korea provides mammogra-
phy tests for screening breast cancer for women aged 40–69 years3. The effectiveness of this screening program, 
however, is controversial mainly because the validity of mammography-based test is lower for Asian women than 
for Caucasians4–8 About 4.8% and 11.1% of breast cancers were diagnosed before age 40 and 45, respectively, in 
the United States between 2005 and 2014. The proportions of these early-onset cases almost tripled for Korean 
women during the same period (13.9% and 29.8%), although overall incidence rate is less than a half of that for 
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Western women9,10. Early-onset breast cancer cases are generally more likely to have higher pathologic grade 
and to be receptor-negative tumors11–14. Given the low predictive value of mammography for Asian women, 
ultrasonographic breast examination might be introduced to improve the validity but at greater cost. An effective 
genetic screening test, if available, might be able to identify women at high-risk of breast cancers for personalized 
prevention programs. So far, to our knowledge, the genetic etiology of high-risk breast cancers is understudied 
particularly for Asian women with more burdens from high-risk breast cancers.
Mutations in BRCA1 and BRCA2 (hereafter referred to as BRCA1/2), the most important genetic susceptibil-
ity markers, account for up to 15% and 30% of the familial recurrence risk (FRR) of overall and high-risk breast 
cancers15. Clinical practice guidelines are well-established for BRCA1/2 mutation carriers16. Conversely, lack of 
proper knowledge has left the BRCA1/2 mutation non-carriers’ genetic counseling largely unattended, although 
these non-carriers with strong family history show similar clinical presentations predictive of BRCA1/2 mutation 
carriers (“BRCAX” cases), with four-fold or greater lifetime risk of breast cancer than the general population17,18. 
In Korea, breast cancer cases with early-onset (age < 40) or other indications suggesting a strong genetic burden 
are entitled to BRCA1/2 mutation testing covered by Korean National Health Insurance. The test has found clin-
ically significant BRCA1/2 mutations for only 15.7% of eligible patients (22.3% of examinees indicated by strong 
family history, and 8.8% by early-onset)19, to make the understanding of “BRCAX genes” a priority. Several studies 
have been conducted to elucidate the genetic architecture of BRCAX cancers20–22. Studies do not have replicated 
the novel loci from each other, suggesting that susceptibility loci for BRCAX might be population-specific, at least 
partly. Asian women might have specific genetic susceptibility for the high-risk breast cancers, but, to our knowl-
edge, no studies have been conducted toward this end.
We conducted a genome-wide search for BRCAX genes involving 1,469 Korean female breast cancer cases 
who were eligible for the BRCA1/2 test but negative for causal mutations. Then, we replicated our findings using 
the Breast Cancer Association Consortium (BCAC) data. We also estimated the role of previously reported sus-
ceptibility loci on the risk of BRCAX occurrence. Finally, we evaluated the impacts and estimated risk of those 
associated markers on high-risk breast cancers for Asians and Europeans.
Results
For the discovery phase, a total of 1,478 Korean BRCAX cases and 5,979 controls were selected with 3,378,933 
markers (flowchart is shown in Supplementary Fig. S1). Characteristics of the participants were described in 
Table 1. Mean age of cases (40.2) was approximately 15 years younger compared to controls (55.1), but allele 
frequencies of associated markers were not significantly different between age group (Supplementary Table S1). 
Among 1,469 cases after quality control, 169 and 288 women had one BRCA1 or BRCA2 mutation with unverified 
significance. For BRCA2 gene, we found 42 variants significantly which are more frequent in the cases com-
pared to the controls (Supplementary Table S2). However, the ClinVar database showed that 40 of these were 
reported to be benign and only two variants (rs2126042 and rs766173) was reported to be benign or have uncer-
tain significance.
Being indicated by early-onset (≤age 40) comprised the largest proportion of the case composite (70.6%), 
followed by having a family history of breast cancer (42.9%).
From the genome-wide association study (GWAS), the genomic inflation factor (ʎGC) was 1.09 and p-values 
were corrected for the inflation factor. Figure 1 and Supplementary Fig. S2 show the Manhattan plot and the 
quantile-quantile plot. Initially, 15 independent loci of single nucleotide polymorphisms (SNPs) showed 
p-values < 10−5. Two SNPs reached genome-wide significance level in the first phase analysis, and both were 
reported before: rs9383936 (p = 1.01 × 10−10, OR = 1.35) on the intron of CCDC170 (near ESR1) and rs4784227 
(p = 9.11 × 10−9, OR = 1.31) on the intron of TOX3. Three previously reported loci (SIAH2, FGFR2, PGAM1P5/
NTN4) and nine new loci also comprised the initial 15 loci. One variant on CDKN2B-AS1 (rs1011970) was previ-
ously associated with breast cancer risk for European descendants23,24, but our study found another variant in the 
proximal regions of the CDKN2B-AS1 gene, rs78545330. These two SNPs constituted separate haplotype blocks 
(r2 = 0.026 for East Asians), and we considered rs78545330 as independent.
The replication set consisted of 1,482 cases (1,194 early-onset cases and/or 390 women with a family history 
breast cancer in first-degree relatives, Asian high-risk cases) and 3,612 control women without family history 
of breast cancer. We compared the characteristics and composite of high-risk breast cancer cases of different 
populations (Supplementary Table S3). Among the initial 15 candidate loci, six variants were statistically signif-
icant (at p-value < 0.05) including two previously known (CCDC170/ESR1, and TOX3) and four novel suscep-
tibility loci. Among four novel loci, rs11154838, located on 6q23.3 (intron of PDE7B), showed associations at 
genome-wide significance level (p-values: 2.27 × 10−8). Other two novel candidate loci (rs78545330 in the intron 
of CDKN2B-AS1 and rs278050 on 13q12.3, 73 Kb 5′ of UBL3), while replicated in Asian high-risk cases at nomi-
nal p-value, did not reach genome-wide significance in the meta-analysis (p-values: 8.56 × 10−8 and 1.63 × 10−6). 
The other novel variant, rs4969001 on SLC39A11, was associated in the opposite direction; thus, it was not con-
sidered for further analysis. We summarize findings of these 15 candidate loci in Table 2. For European high-risk 
breast cancers, all three novel susceptibility loci did not show meaningful associations (p-values = 0.34, 0.24 and 
0.50).
When we conducted a meta-analysis by the receptor-status, four loci of the initial 15 candidate loci from the 
GWAS showed receptor-status specific associations with even smaller sample sizes. We only focused on findings 
where smaller subgroup resulted in the stronger association, to reduce the influence of sample size variation. 
rs60538652, on SIAH2, rs2912774 on FGFR2 and rs67129489 near PGAM1P5/NTN4 were more strongly associ-
ated with ER+ or PR+ cases, while rs9383936 near ESR1 was more strongly associated with ER− or PR− breast 
cancers (Pheterogeneity <0.05). It is noteworthy that markers at SIAH2, FGFR2, and PGAM1P5/NTN4 showed an 
increased level of significance in subgroup analyses despite smaller sample sizes. None of the variants identified 
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Variables No. (%)
Age (years old), mean ± sda 40.24 ± 9.13
BRCA1/2 mutationb
BRCA1–neg & 
BRCA2–uv 288 (19.6%)
BRCA1–uv & 
BRCA2–neg 169 (11.5%)
Both negative 1012 (68.9%)
Age of breast cancer onset
≤40 1037 (70.6%)
40–45 143 (9.7%)
>45 289 (19.7%)
Family history of breast cancer in the first 
or second degree relatives
no history 908 (61.8%)
1 492 (38.2%)
2 60 (4.1%)
3 9 (0.6%)
Family history of ovarian cancer in the 
first or second degree relatives
no history 1399 (95.2%)
1 68 (4.6%)
2 2 (0.1%)
Disease history of cancers other than 
breast cancer 72 (4.9%)
Bilateral breast cancer 122 (8.3%)
Receptor status
  Estrogen receptor
negative 465 (31.7%)
positive 891 (60.7%)
unknown 113 (7.7%)
  Progesterone receptor
negative 496 (33.8%)
positive 879 (59.8%)
unknown 94 (6.4%)
  HER2 receptor
negative 924 (62.9%)
positive 275 (18.7%)
equivocalc 139 (9.5%)
unknown 131 (8.9%)
  Triple-negative 223 (15.2%)
Table 1. Characteristics of breast cancer cases (n = 1,469). aSd: standard deviation. bNeg: negative, uv: 
unverified mutation. cImmunohistochemistry (IHC) 2+, Fluorescence In Situ Hybridization (FISH) unknown.
Figure 1. Manhattan plot. The red horizontal line represents the genome-wide significance threshold 
of p-value = 5.0 × 10−8 and the blue horizontal line represents the suggestive significance threshold of p-
value = 1.0 × 10−5. For significantly associated regions, SNPs with p-value less than 10−3 are highlighted in 
green and the replicated genes are marked in bold.
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from the GWAS were differentially associated according to HER2 receptor status or being TNBC. More details 
about the receptor-status-wise analyses were described in Supplementary Table S4.
Three novel candidate regions were visualized using LD plots and regional association plots (Supplementary 
Fig. S3) and annotated for regulatory elements (Supplementary Table S5). Two markers (rs6905776 and 
rs12174235), in the same LD block with rs11154838 on PDE7B, were annotated for regulatory elements (GWAS 
p-values: 1.63 × 10−6 and 2.72 × 10−5). rs78545330 on the intron of CDKN2B-AS1 and correlated markers showed 
strong evidence of regulatory function from multiple tissues including breast tissues, while rs1011970 (previously 
reported SNP) was not annotated for regulatory elements. East Asians have a risk allele of rs78545330 (A, allele 
frequency = 0.21) three times more frequently than Europeans (0.08). We presented the haplotype structures of 
this region between Asian and Europeans (Supplementary Fig. S4). For East Asians, multiple LD blocks were 
more distinct, and the LD between rs78545330 and rs1011970 was weak in East Asians (r2 = 0.02), indicating 
that rs78545330 is a novel candidate variant. When we examined the genetic regions harboring candidate vari-
ant near UBL3, the region consisted of two independent LD blocks, and rs278050 and correlated SNPs showed 
enhancer-related histone marks in several tissues including breasts and mammary tissues. Also, rs73444211 in the 
other LD block near UBL3 participated in diverse regulatory functions.
Results from eQTL analyses for three candidate loci also showed evidence of associations with gene-expression 
levels of different tissues (Supplementary Table S6). The risk allele T of rs11154838 was associated with PDE7B 
gene-expression level in blood vessels (p-value = 0.001), but not with other tissues. rs78545330 on CDKN2B 
showed strong associations with gene expressions in multiple tissues. The risk allele substantially decreases the 
expression of CDKN2B, a tumor suppressor gene (p-value = 1.7 × 10−13, effect size = −0.44). rs278050 near UBL3 
also altered cis-gene regulation in several tissues.
When we replicated findings from the previous studies, a part (24 for Korean BRCAX, 55 for European 
and 14 for Asian high-risk breast cancers) of 92 loci from the GWAS catalog showed meaningful associations 
(p-value < 0.05 with the same direction of association as in the previous reports, Supplementary Table S7). 
SNP Chr
Position 
(hg19)
Nearest 
Genes 
(distance to 
gene) Function
Risk 
Allele 
(fwd)
RAF in 1 kG 
Phase3a Korean BRCAX cases (initial)
Asian high-risk cases 
(replication) Meta-analysis
EAS EUR
RAF in 
casesa P-value
OR (95% 
CI)b
RAF 
in 
casesa P-value
OR (95% 
CI)b P-value
OR (95% 
CI)b Pheteroc
rs60538652 3 150473606 SIAH2 Intron A 0.61 0.98 0.65 6.24.E-07 1.26 (1.15–1.38) 0.73 0.072
1.13 
(0.99–1.28) 3.25.E-07
1.21 
(1.13–1.31) 0.16
rs11154838 6 136290942 PDE7B Intron C 0.72 0.65 0.75 1.28.E-06 1.27 (1.15–1.40) 0.83 0.005
1.26 
(1.07–1.49) 2.27.E-08
1.27 
(1.17–1.38) 0.96
rs9383936 6 151944614
3′ of 
CCDC170 
(2.3 Kb), 5′ 
of ESR1 (3.3 
Kb)
Intergenic A 0.31 0.08 0.34 1.01.E-10 1.35 (1.23–1.48) 0.34
1.05.E-
06
1.3 
(1.17–1.44) 6.35.E-16
1.33 
(1.24–1.42) 0.58
rs10953105 7 93622247 BET1 3′ UTR G 0.86 0.97 0.88 1.13.E-06 1.37 (1.21–1.56) 0.91 0.192
1.14 
(0.94–1.38) 1.81.E-06
1.30 
(1.16–1.44) 0.11
rs2350923 8 62605259 ASPH Intron T 0.72 0.70 0.76 7.75.E-07 1.28 (1.16–1.42) 0.27 0.750
1.02 
(0.92–1.13) 0.250
1.14 
(0.91–1.44) 0.00
rs78545330 9 21995941 CDKN2B-AS1 Intron A 0.21 0.08 0.26 3.41.E-06
1.26 
(1.14–1.39) 0.20
5.73.E-
03
1.19 
(1.05–1.35) 8.56.E-08
1.23 
(1.14–1.33) 0.47
rs10814070 9 34129839
3′ of 
DCAF12 
(3.1 Kb)
Intergenic T 0.71 0.25 0.75 1.93.E-06 1.26 (1.15–1.39) 0.65 0.469
0.96 
(0.87–1.07) 0.465
1.10 
(0.85–1.44) 0.00
rs2912774 10 123348662 FGFR2 Intron T 0.38 0.43 0.42 5.96.E-07 1.25 (1.14–1.36) 0.43 0.052
1.11 
(1.00–1.21) 5.60.E-07
1.18 
(1.10–1.25) 0.06
rs9418690 10 128809949 DOCK1 Intron C 0.73 0.76 0.76 1.08.E-06 1.28 (1.16–1.41) 0.82 0.819
1.02 
(0.85–1.23) 0.183
1.16 
(0.93–1.44) 0.04
rs4964006 12 26770889 ITPR2 Intron T 0.95 0.69 0.98 1.52.E-06 1.96 (1.49–2.58) 0.95 0.804
0.97 
(0.76–1.24) 0.366
1.38 
(0.69–2.75) 0.00
rs67129489 12 96016957
5′ of 
PGAM1P5 
(26.0 Kb), 
5′ of NTN4 
(34.6 Kb)
Intergenic G 0.13 0.32 0.15 9.31.E-07 1.36 (1.20–1.53) 0.06 0.976
1.00 
(0.77–1.32) 0.226
1.20 
(0.89–1.60) 0.05
rs278050 13 30436968 5′ of UBL3 (73 Kb) Intergenic C 0.19 0.23 0.21 3.89.E-06
1.28 
(1.15–1.42) 0.19 0.050
1.13 
(1.00–1.28) 1.64.E-06
1.22 
(1.12–1.32) 0.14
rs4784227 16 52583143 TOX3 Intron T 0.26 0.25 0.32 9.11.E-09 1.31 (1.19–1.44) 0.29
6.24.E-
05
1.25 
(1.12–1.39) 3.26.E-12
1.28 
(1.20–1.38) 0.49
rs4969001 17 70980127 SLC39A11 Intron T 0.89 0.96 0.86 6.53.E-06 1.32 (1.17–1.49) 0.89 0.041
0.85 
(0.73–0.99) 0.780
1.06 
(0.69–1.64) 0.00
rs73107564 20 36263775 — Intergenic A 0.89 0.81 0.89 1.81.E-07 1.43 (1.25–1.63) 0.87 0.541
0.96 
(0.83–1.10) 0.432
1.17 
(0.79–1.73) 0.00
Table 2. Genomic loci associated with breast cancer (P-value < 10−5). aRAF: risk allele frequency, EAS: East 
Asian, EUR: European. bOR: odds ratio, CI: confidence interval. cPhetero: P-value for heterogeneity. Fixed effect 
model was used if p-value for heterogeneity exceeds 0.05; otherwise random effect model was used.
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Generally, replicated variants showed larger risk for BRCAX or high-risk cancers than the previous reports for 
all breast cancers. Since the majority of known susceptibility markers were reported from studies of European 
populations, the number of replicated markers was larger for European cases compared with Korean or Asian 
cases. However, the sum of %FRR (Σ%FRR) of each replicated marker was largest for Korean BRCAX cases 
(29.8%), followed by European high-risk cases (24.0%) and Asian high-risk cases (10.6%). Three novel candidate 
variants accounted for additional 9.6% and 3.0% FRR for Koreans and Asians. It is noteworthy that three repli-
cated variants on FGFR2, TOX3, and ESR1 have been reported in previous searches for BRCAX genes20–22. These 
variants were also associated with overall breast cancer risk in multiple studies25. Other candidate loci reported 
from previous BRCAX studies were not replicated in this study20–22. Finally, among the breast cancer predisposi-
tion genes with moderate/high-penetrance16,26, seven genes (BMPR1A, PTEN, CDH1, NF1, RAD51C, BRIP1, and 
CHEK2) were replicated for Korean BRCAX (eight for Asian and 15 genes for European high-risk breast cancers, 
Supplementary Table S8). The estimated contributions from the moderate/high-penetrance variants varied by the 
populations, accounting for 4.2%, 13.2%, and 7.9% of overall high-risk breast cancers for Koreans, Asians, and 
Europeans.
We estimated the increase in risk with increase in genetic risk score (GRS) for each population (Fig. 2A). 
Predicted risk (OR) by GRS was highest for Korean BRCAX cases, and the OR increased upon adding newly iden-
tified markers for both Koreans (OR: from 2.95 to 3.09) and Asians (OR: from 1.60 to 1.71). Also, we estimated 
the genetic risk of BRCAX according to genotypes of “shared between populations (FGFR2/TOX3/ESR1, reported 
from multiple BRCAX studies including ours)”. The estimated increases in the risk of BRCAX or high-risk breast 
cancers from the variants on FGFR2, TOX3, and ESR1 were quite similar across populations (ORs for highest 
compared to lowest tertile = 2.2 to 2.4, Fig. 2B). When we stratified and compared the estimated risk of GRSs cal-
culated from the three novel and 21 replicated (after exclusion of three markers on FGFR2/TOX3/ESR1 among 24 
replicated variants) “Asian-specific BRCAX” markers according to “shared between population” (FGFR2/TOX3/
ESR1) genotype status, those with multiple risk alleles of FGFR2/TOX3/ESR1 showed steeper increases in risk for 
breast cancers, compared with those in none or one allele groups (Fig. 2C).
Discussion
From a genome-wide search, three candidate loci were newly identified with suggestive evidence of functional 
involvement. The three novel loci identified by this study might tag the closely-located functional variants based 
on the downstream analyses. The marker itself, or markers within the LD block, have marks for regulatory ele-
ments, suggesting these SNPs themselves or variants tagged by the SNPs might be associated with the patho-
physiology of BRCAX breast cancer development. PDE7B (phosphodiesterase 7B) encodes a cyclic adenosine 
monophosphate (cAMP)-specific phosphodiesterase and CDKN2B (cyclin-dependent kinase 4 inhibitor B) is 
a known tumor suppressor gene27. The risk allele of the top hit (rs78545330) on CDKN2B-AS1 showed strong 
evidence of reducing gene expression level of this tumor suppressor gene.
Figure 2. Predicted risks by genetic risk scores. (A) Relative risks by genetic risk scores (GRSs) across the 
population. For two different types of markers sets (“BRCAX-known”: markers replicated for Korean BRCAX 
cases among previously reported breast cancer-associated markers from the GWAS catalog; “BRCAX-
known + novel”: three novel candidate markers added to replicated markers), a predictive performance by 
GRSs was estimated for Korean BRCAX, Asian, and European high-risk cases. For BRCAX-known markers, 
predictive performance by GRSs was highest for Korean BRCAX followed by European and Asian high-risk 
cases. When three novel markers were added, however, prediction improved for Asians compared to Europeans. 
(B) Predicted risks of breast cancer according to three risk groups using the number of risk alleles of three 
consistently reported markers from three previous GWAS of BRCAX across the population: FGFR2 (rs2912774), 
TOX3 (rs4784227), and ESR1 (rs9383936). (C) Predicted BRCAX risks by GRSs using BRCAX-known markers 
by tertile groups of three global BRCAX-associated markers (on FGFR2, TOX3, and near ESR1): circle symbols 
are for low-risk group (T1), triangle symbols are for moderate risk group (T2), and square symbols are for high-
risk group (T3).
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When we examined the association of newly identified markers with overall Asian cases including late-onset 
and sporadic breast cancers of BCAC, both rs11154838 (PDE7B) and rs78545330 (CDKN2B-AS1) showed 
stronger level of significance but with smaller effect sizes (ORs: 1.16 and 1.14 for all breast cancers, 1.26 and 1.19 
for high-risk breast cancers), but rs278050 (UBL3) was not associated (p = 0.2). For European cases, rs78545330 
was replicated for overall cases only (p = 0.017, OR = 1.04; high-risk breast cancer: p = 0.2), but other two novel 
candidate loci did not show significant associations. One possible explanation for this population-specific man-
ner of association is that genetic susceptibility to BRCAX might comprise multiple genetic loci which are only 
partly shared between populations. The newly identified candidate loci might be Asian-specific and also more 
associated with the early-onset type of high-risk cancers. When we estimated OR according to GRS, the addition 
of novel variants to known markers increased the risk for Korean and Asian, but not for European high-risk breast 
cancers.
It is interesting that some of the markers shared between high-risk and general breast cancers showed aug-
mented impacts on the BRCAX cancers. For example, rs12628403 on the intron of APOBEC3A alone explained 
6.5% of FRR (OR = 1.49), compared with OR = 1.17 for overall breast cancers. Also, rs10069690 on the intron 
of TERT was replicated for BRCAX with higher risk estimate (OR = 1.24) than the OR (1.10) from the original 
studies. These findings are in line with the findings from the colorectal cancer study28: some SNPs show stronger 
associations with high-risk cases with larger impacts. Our findings suggest that role of some variants might not be 
same between in high-risk and in general breast cancers, although they are associated with both types. It might be 
logical to infer that a substantial part of the genetic risk of high-risk breast cancers comprises common variants 
overlapping with general types of breast cancers but at augmented risks.
Among replicated markers, FGFR2 (rs2912774), TOX3 (rs4784227), and ESR1 (rs9383936) deserve a spe-
cial remark. All three previous GWAS for BRCAX replicated FGFR2, and multiple studies replicated TOX3 and 
ESR120–22. Our study also replicated these three variants for high-risk breast cancers in all population data. When 
we compared the estimated risk of these three variants, the estimated risk was quite similar between three popu-
lations (Korean BRCAX, Asian and European high-risk cancer, Fig. 2B). This finding suggests that shared genetic 
susceptibility toward high-risk breast cancer might exist across the population. These three variants might be 
only the tip of the iceberg. Our study did not examine sequence level variation which might also be shared across 
populations. At least, our findings support that a part of common variants associated with low-risk breast cancers 
also has their roles in the susceptibility of high-risk breast cancer.
In our study, about 62% of Korean BRCAX cases, 48% and 25% of Asian and European high-risk cancers were 
non-familial early-onset cases. Europeans have more familial cancers probably due to higher prevalence than 
Asians or inclusion criteria of each study. It is not clear whether two major indications of being a “high-risk” type, 
i.e., early-onset and familial cases have differences in their genetic constitutions. In our study, differences in the 
association and effect size between populations for some variants might stem from the differences in this case 
composites.
When GRS was re-estimated according to the risk allele counts of FGFR2/TOX3/ESR1, the estimated risk from 
GRS not only was larger but also showed a steeper increase suggesting an effect modification. The risk modifi-
cation according to FGFR2/TOX3/ESR1 was more evident for BRCAX (Korean), partly because of its strict case 
definitions (Fig. 2C).
We also evaluated the impact of known and novel susceptibility loci for high-risk breast cancers. The estimated 
Σ%FRR from replicated markers was 29.8% for Korean BRCAX with 24 markers. The findings from replicated 
markers (29.8% FRR) might not be attributed to so-called “winner’s curse” bias, an inflated impact estimation 
in the discovery set itself, because the Korean BRCAX served as a replication set. Three novel loci accounted for 
9.6% of the FRR for Korean BRCAX. The impact of three novel loci on Korean BRCAX cases, however, might 
be inflated for having used the discovery set on itself. Novel candidate loci added 3.0% to Asian, but none to 
European high-risk cancers. When the %FRR of three novel loci was estimated from all types of Asian breast can-
cers, the estimate decreased to 0.75%, suggesting that these loci mainly account for the genetic risk of high-risk 
breast cancers.
Sum of FRR (Σ%FRR) from common variants are considerably compatible between populations: 29.8–39.4% 
for Koreans, and 24.0% for Europeans, and 10.6–13.6% for other Asians. One reason why Σ%FRR is smaller for 
Asians might be explained their heterogenic ethnic compositions (In this study, Asian high-risk breast cancer 
cases consisted of Japanese 28%, Chinese 30%, Asian American 16%, and others 25%). If associated markers 
have not been identical between ethnic groups, some variants more specifically associated with certain popula-
tions might be missed. Moreover, replication was conducted using 92 markers, most of them were reported from 
studies of European ancestry. Also, a smaller sample size could be another reason for fewer replicated markers in 
Asians. Wen et al.’s study replicated 44 of 78 previously reported loci involving 11,760 overall breast cancer cases 
of East Asians29. When we performed an analysis including late-onset breast cancer cases (6,130 cases and 6,371 
controls), we could have replicated 24 loci (10 consistent, 12 added and two removed loci). Whether the differ-
ence is attributable to the power or the differences in the genetic susceptibility between high-risk and late-onset 
breast cancers is not conclusive. The six additional loci, however, did not show any clues of possible association 
with high-risk breast cancers (p > 0.3), and we believe the differences in the genetic architecture between spo-
radic/low-risk and familial/high-risk breast cancers might explain a part of the discrepancy. Korean data might 
have shown compatible Σ%FRR of high-risk breast cancers with Europeans, partly due to their size and stricter 
definition for cases. We believe it might be reasonable to interpret the findings that common variants explain as 
much Σ%FRR of high-risk cancers as BRCA1/2 mutations. We also examined the associations and their impacts 
on breast cancer predisposition genes with moderate/high-penetrance. Although imputed markers covered most 
of the known variants, our approach might have materially underestimated their impacts, and cannot replace the 
findings from the sequence-based approach.
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A proper genetic screening program for BRCA/BRCAX, if implemented, might contribute to detecting 
high-risk women for providing personalized screening program such as ultrasonography. Additionally, it will 
provide information for consulting the relatives of BRCAX cases. Findings from our study support the necessity 
and possibility of developing a new genetic screening for BRCAX. However, our study alone does not provide 
other important information necessary for effective genetic screening, in particular, estimates of penetrance and 
predictive values of the test. Estimating sensitivity and specificity of BRCAX-associated markers are required first 
in larger data. Also, this study considered the genetic markers associated with the occurrence of high-risk breast 
cancer, and their potential implications for detecting high-risk populations. To provide evidence that support a 
new genetic screening program, further data about a reduced mortality rate from breast cancer might be required, 
but these are beyond scope of ours.
We believe that this study confers some advantages over previous BRCAX studies. First, the number of 
test-proven BRCA-negative cases was not modest (n = 1,469), and more than 11,300 high-risk breast cancer cases 
were included, larger than previous studies20–22. Second, all the BRCA1/2 mutation status was more accurately 
identified by standard sequencing analysis of each BRCA1 and BRCA2 exon. Third, we selected high-risk cases 
with genetic burdens using the similar indications as BRCA1/2 mutation test: age of onset, family history, history 
of other malignancy, and bilateral cancers. Applying these strict indications might have enabled us to select cases 
with high genetic burdens. Fourth, we attempted to re-evaluate the findings from our own GWAS study and 
previous studies jointly including both common variants in the GWAS catalog, and moderate/high-penetrance 
genes. This approach might have provided more comprehensive views on the genetic architecture of BRCAX and 
high-risk breast cancers. Similarly, this approach enabled us to estimate the impacts of associated markers on 
the occurrence of BRCAX for different populations and context. The impact estimates from our study will confer 
implications for genetic screening test of high-risk women. Finally, to our knowledge, this is the first Asian study 
focused on BRCAX cases, where epidemiologic features suggest unique susceptibility might exist.
This study also has several limitations. First, exact information about BRCA1/2 mutation status was scarce, and 
not available for most studies of the BCAC. Applying the criteria for high-risk cancers only which were not con-
firmed to be BRCA1/2-negative might have decreased the power of detecting associated markers. Nevertheless, 
this limitation might not have influenced toward increasing false-positive findings in the study. Second, Asian 
cases in the BCAC data were limited so that the criteria for early-onset age were relaxed to the age 45, while the 
same criteria for having family history was applied. These relaxed criteria in the replication data might have 
reduced the power to detect susceptibility loci more specific to the BRCAX cases. When we estimated the associ-
ations for replicated and novel loci using different age criteria for Asian high-risk cases (938 cases for replication 
set when age 40 was used), direction and strength of associations were largely same with slightly less statisti-
cal power: the number of replicated markers and Σ%FRR of them declined from 14 (10.6%) to eight (9.0%). 
However, ORs of three novel markers increased and Σ%FRR increased from 3.0% to 3.8% accordingly. Third, 
even with the sample size of 1,469 confirmed BRCAX cases, our study has limitations in power to newly detect 
relatively rare alleles (0.01 < MAF < 0.05) because of the scarcity of high-risk cancer cases. We estimated that the 
relative risk should exceed 2.5 to be detected as novel with our sample size30. Fourth, although this not being the 
main purpose of our study, when we attempted to replicate the “moderate/high-penetrance” variants, the effects 
might have been underestimated because some of the variants were not exactly identified in our imputed geno-
type data. We believe the estimated impacts from these genes should have been underestimated. The estimated 
impact of the common variants, however, is not likely affected by this limitations, because the frequency of the 
common risk alleles is independent of the rare alleles. Fifth, the replication analysis of previously reported loci 
might have inflated as the replication set could include data of the discovery set. Finally, as the mean age was 
different by affection status in the discovery set (cases: 40.2, controls: 55.1), the age was not used as a covariate, 
because we did not observe any difference in allele frequencies between controls (older) and those in the popu-
lation with same age with cases (younger) (Supplementary Table S1). If there are some susceptibility loci which 
are expressed in an age-dependent manner, those markers could not have considered in this study. However, we 
believe older controls might be more appropriate in part due to they have lower chance of developing breast can-
cer compared to younger controls with similar mean age with the cases (40 years old).
In conclusion, we have identified novel common susceptibility loci from GWAS and replicated some of both 
common/low-penetrance and rare/high-penetrance variants which were reported previously. We also evaluated 
the contribution of those susceptibility loci including ours, to high-risk breast cancers of multiple populations. 
Our findings also suggest that high-risk breast cancers, particularly for Asians, might consist of multiple layers 
with similar importance, including BRCA1/2, moderate/high-penetration genes, and selected common variants 
with augmented effects. Our study might add information to consider prevention strategy of early-onset and 
high-risk breast cancers in Asia, and also to the genetic counseling for relatives of the high-risk breast cancer 
patients without a mutation in BRCA1/2 genes.
Methods
Study design and participants of the discovery set. We conducted a case-control GWAS. Breast 
cancer patients were selected from the Korean Hereditary Breast Cancer (KOHBRA) study. Breast cancer 
patients with one of following five conditions and family members of BRCA1/2 mutation carriers were eligible 
for BRCA1/2 gene test provided by the Korean National Health Insurance - family history of breast or ovarian 
cancer, diagnosed at age 40 or younger, bilateral breast cancer, male cases, or diagnosed with another primary 
malignancy. The KOHBRA study enrolled those who provided informed consent among the “BRCA1/2 gene test 
eligible” cases and their family members. The detailed information of the KOHBRA study has been described 
previously31 and in Supplementary Notes. From the KOHBRA participants, unrelated women (estimated identity 
by descent < 0.125) who met the following criteria were included in this study:
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 (i) Breast cancer patients who were tested to be free of clinically significant BRCA1/2 gene mutation (clinically 
unverified mutation cases were included)
AND at least one of the following
 (ii) Diagnosed as breast cancer before or at age 40; OR having one or more relative(s) with breast/ovarian 
cancer; OR bilateral cases; OR previously diagnosed as other cancer.
We used data from Korean Genome Epidemiology Study (KoGES) as control. The profiles of KoGES consor-
tium was described elsewhere32 and in Supplementary Notes. Genetically unrelated (estimated identity by descent 
<0.125) Korean women without family history of breast or ovarian cancer were included. All participants gave 
informed written/oral consent, and this study was approved by the Institutional Review Board of Asan Medical 
Center, Seoul, Republic of Korea. This study was conducted in accordance with the World Medical Association 
Declaration of Helsinki.
Genotyping and imputation methods. Cases were genotyped using Illumina OncoArray-500K 
Beadchip at the University of Southern California Epigenome Center, CA, USA. Peripheral blood samples 
(20 ml) were collected at baseline, and they were divided, treated and stored within 24 hours of sampling. We 
excluded individuals with low call rate (<95%) and SNPs with genotype call rate <95%, minor allele frequency 
(MAF)<1%, evidence for deviation from Hardy-Weinberg equilibrium at p-value < 10−9, or poor cluster plots. 
Genotype data were phased and imputed using SHAPEIT and IMPUTE2 software respectively, and East Asian 
data from the 1000 Genomes Project (1 kG) Phase 3 were used as reference33–36. From imputed markers, SNPs 
with info score greater than 0.95 were included. We genotyped cases and controls with four different platforms of 
dense genome-wide SNP arrays and conducted standard quality control and imputation process. And the batch 
effect detected through association analysis of control data genotyped from different platforms was removed 
(p < 0.01). For post-imputation quality control, markers with high missing rate >10%, minor allele frequency 
(MAF)<1%, evidence for deviation from Hardy-Weinberg equilibrium at p-value < 10−6 were excluded. More 
detailed information was described in Supplementary Notes.
BRCA1 and BRCA2 genomic mutation analysis. Genomic DNA was extracted from the partici-
pants’ peripheral blood samples. For BRCA1/2 mutation testing in cases, 22 coding exons of BRCA1 and 26 
coding exons of BRCA2 were scanned through fluorescence-based conformation sensitive gel electrophoresis 
(F-CSGE) and denaturing high-performance liquid chromatography (DHPLC). For a subset of PCR products 
with aberrant patterns, direct sequencing was performed on an ABI3100 or ABI3700 (Applied Biosystems, CA) 
or a MegaBACE500 (GE Healthcare, UK) genetic analyzer. In this study, the definition of a genetic mutation is 
restricted to the protein-truncating mutation and the missense mutation, which are known to be associated with 
the disease. This study also includes the participants with a clinically unverified mutation in BRCA1/2 genes. 
More detailed information about BRCA1/2 mutation analysis has been described before31,37. Since this study also 
includes the cases with unverified mutation on BRCA1/2, we examined whether non-pathogenic variants on 
these genes are more frequent in the cases compared to controls at p-value of 0.05. And we searched them at the 
ClinVar database.
Statistical analyses for the genome-wide search. GWAS was carried out using logistic regression 
by trends test of PLINK version 1.0738. For visualization of the results, Manhattan plot and quantile-quantile 
(QQ) plot were generated using R package ‘qqman’39. Principal component analysis (PCA) was conducted using 
EIGENSTRAT, and the first three principal components were used for adjustment40. Since most cases were 
early-onset breast cancer and cohorts for control recruited adults with a limited age range, mean age was much 
younger in cases than controls. Thus, allele frequencies of significant markers were presented by affection status 
and age groups, rather than adjusting for age.
Replication and meta-analysis of newly identified loci. For the replication of the initial candidate 
loci, imputed data of Asian population from the BCAC were used. The overall description about the BCAC was 
previously reported41 and in Supplementary Notes. Since most of the cases in the BCAC lack BRCA1/2 mutation 
information, we included high-risk breast cancers defined as: breast cancer cases diagnosed before or at age 45 or 
cases with family history of breast cancer in first degree relatives. For controls, women without family history of 
breast cancer were included among the BCAC control data.
For newly identified loci, we conducted meta-analyses using fixed or random effect model according to evi-
dence of heterogeneity (fixed effect model was used if p-value for heterogeneity exceeds 0.05). Also, we conducted 
subgroup analyses by three receptor status (estrogen, progesterone, and HER2 receptor). P-values for heteroge-
neity by receptor status were calculated using a Cochran’s Q test, and a p-value of 0.05 was used to determine 
heterogeneity.
Downstream analyses of newly identified loci. For newly identified loci which were replicated using 
Asian high-risk cases from the BCAC, downstream analyses were performed. These regions were visualized by 
linkage disequilibrium (LD) plots and regional association plots. LD plots were created using control data with 
‘LDheatmap’ package in R42. And regional association plots were created by Locuszoom using East Asian popu-
lation of the 1 kG Phase 3 as reference43.
Functional information of novel loci was annotated using Encyclopedia of DNA elements (ENCODE) project 
and HaploReg version 4.144,45. Novel SNPs and correlated markers with r2 > 0.8 from East Asian population were 
explored. Results of expression quantitative trait loci (eQTL) analyses were found from the Genotype Tissue 
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Expression (GTEx) portal46. Associations between novel markers and expression of the nearest gene of each SNP 
for all available tissues and associations between these markers and nearby genes with a window size of 1 Mb for 
the tissue showing the most significant associations were retrieved.
Replicating susceptibility loci previously associated with breast cancers. We estimated asso-
ciations between previously reported breast cancer susceptibility loci and BRCAX cases and how the signif-
icance of associations and their effect sizes differ. First, we selected markers associated with breast cancer at 
p-value < 10−5 from the NHGRI-EBI GWAS catalog25. We also examined the candidate loci from three previous 
BRCA1/2-negative cancer GWAS20–22. Finally, the variants on genes associated with increased risk of breast or 
ovarian cancer listed in the guideline for genetic screening of high-risk breast cancers (suggested by the National 
Comprehensive Cancer Network, NCCN) or breast cancer predisposition genes used in a recent article were 
evaluated in this study16,26. Seventeen genes listed on the NCCN guideline were ATM, CDH1, CHEK2, MSH2, 
MLH1, MSH6, PMS2, EPCAM, NBN, NF1, PALB2, PTEN, RAD51C, RAD51D, STK11, and TP53, except for 
BRCA1/2; six additional genes suggested from the study by Wong et al. were BARD1, BMPR1A, FANCC, SMAD4, 
VHL, and XRCC2. Variants in gene regions ± 10 kB were tested for association. In this analysis, the markers with 
MAF < 1%, which were excluded during quality control, were also included. Independent (r2 > 0.3) SNPs with 
p-value < 0.01 were included for impact estimation.
To assess the impact of reported loci in the occurrence of BRCAX cases, we estimated the FRRs from Korean 
BRCAX women, Asian and European high-risk women using the BCAC data (cases with age of onset <45 or 
with a family history of breast cancer in first-degree relatives, for both Asian and European data). The fraction 
of FRR (%FRR) explained by markers was calculated as ln(λ)/ln(λ0) where lambda (λ) is the FRR to a relative of 
an affected individual and λ0 is the overall FRR. λ is calculated as (pr2 × q)/(pr + q)2 where p is the frequency of 
the risk allele in the general population, q equals 1 − p, and r is the per-allele OR. And λ0 is assumed to be 1.8 as 
reported from the previous article47,48. For comparison of FRR explained by each SNP, we applied the same allele 
frequencies from the East Asian or European data from the 1 kG Phase 3 and different odds ratios (ORs) from 
each analysis.
Impact analysis for novel and replicated loci. To compare predictive power among different groups, 
we estimated ORs according to GRSs. GRSs were calculated as a weighted sum of the number of risk alleles, in 
which the weight was taken as the natural log of the OR from association analyses. ORs by quintiles of GRS were 
estimated using the first quintile as the reference. We compared the predictive power of BRCAX by the different 
set of markers for different populations (Korean BRCAX, Asian and European high-risk cases).
We re-evaluated the ORs from polygenic GRS, by stratifying subjects according to their risk alleles associated 
with BRCAX in multiple studies20–22. GRSs were calculated using markers replicated for Korean BRCAX among 
previously reported markers in breast cancer from the GWAS catalog (“BRCAX-known”), and with novel candi-
date markers from the GWAS added to replicated markers (“BRCAX-known + novel”).
Data Availability
The datasets generated and/or analysed during the current study are available in the Open Science Framework 
repository, https://osf.io/a7kn5/. The data that support the findings of this study are available from BCAC but 
restrictions apply to the availability of these data, which were used under license for the current study, and so are 
not publicly available. Data are however available from the authors upon reasonable request and with permission 
of the BCAC group.
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